A Multi-center, Phase Ia/Ib, Open Clinical Study to Evaluate the Safety and Efficacy of TWP-101 in Patients With Advanced Solid Tumor
Latest Information Update: 04 Jan 2024
At a glance
- Drugs Sytalizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shandong TheraWisdom Biopharm
- 20 Jul 2021 Planned initiation date changed from 30 Jun 2021 to 30 Aug 2021.
- 10 May 2021 New trial record